Journal of Clinical Oncology
Articles in this Issue
Circadian immune coherence and readiness as time-aware early endpoints in a real-world NSCLC cohort treated with immune checkpoint inhibitors.
e23114 Background: Immune biomarkers guiding immune checkpoint inhibitor (ICI) therapy are commonly assessed as static bas...
Characterizing the genomic landscape of Langerhans cell histiocytosis using the AACR Project GENIE database.
6572 Background: Langerhans cell histiocytosis (LCH) is a rare neoplasm characterized by the abnormal clonal proliferation...
A context-constrained oncology agent for automated, guideline-concordant treatment decision support in precision oncology.
1620 Background: Precision oncology requires biologically plausible, clinically executable decisions aligned with regulato...
Safety and pharmacokinetics (PK) of lurbinectedin (lurbi) in pediatric patients (pts) with relapsed/refractory (R/R) solid tumors and preliminary antitumor activity in pediatric and young adult pts with R/R Ewing sarcoma (EwS): Results from a phase 1 study.
11518 Background: About 30% of pediatric cancers are solid tumors. EwS is the second most common bone tumor among children...
Prognostic value of early NLR normalization in MSI-H mCRC: A real-world analysis.
e15625 Background: Immune Checkpoint Inhibitors (ICIs) are the standard of care first line for Microsatellite Instability-...
Decision-making and regret after radical cystectomy in patients with bladder cancer: An international cross-sectional survey.
e16605 Background: Radical cystectomy (RC) is the recommended treatment for Bacillus Calmette-Guérin-unresponsive high-ris...
<i>UGT1A1</i> gene variants associated with irinotecan toxicity in patients from northeastern Mexico.
e15142 Background: Genetic variants in the UGT1A1 gene affect Irinotecan metabolis...
QL1706 combined with nab-paclitaxel and gemcitabine as first-line treatment for locally advanced or metastatic pancreatic adenocarcinoma: A prospective, multicenter, single-arm phase II study.
4203 Background: First-line chemotherapy with nab-paclitaxel and gemcitabine (AG) provides limited efficacy in advanced pa...
Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib + panitumumab efficacy and prognosis in <i>KRAS</i> G12C–mutated colorectal cancer (mCRC): Results from phase 3 CodeBreaK 300.
3511 Background: Phase 3 CodeBreaK 300 (NCT05198934) explored two doses of sotorasib (soto) (240 mg and 960 mg) in combina...
Epigenetic reprogramming of allogeneic NK cells via antigen-specific “training” to generate target-specific memory-like NK cells for B-cell lymphoma without genetic engineering.
2546 Background: Clinical application of CAR-NK cells is restricted by manufacturing complexity, cost, and potential genot...
Resistance mechanisms and efficacy of first-line alectinib and sequential treatments in advanced <i>ALK</i> + NSCLC: Real-world outcomes from a multicenter, observational study in Japan (ALCURE).
8604 Background: First-line (1L) alectinib has shown superior progression-free survival (PFS) vs crizotinib in advanced...
The use of miR-5193 to predict oxaliplatin chemosensitivity in colorectal cancer: Integrated in silico, in vitro, and clinical evidence.
3527 Background: Outcomes with first-line chemotherapy in metastatic colorectal cancer (mCRC) are heterogeneous. We evalua...
Early changes in PROSTest, a blood-based mRNA assay, as a predictor of outcomes of <sup>177</sup> LuPSMA radioligand therapy and chemotherapy in metastatic castration-resistant prostate cancer.
e17067 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains associated with heterogeneous responses...
Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukemia (Ph <sup>+</sup> BCP-ALL).
6513 Background: Olverembatinib, a third-generation BCR::ABL1 TKI, has demonstrated clinical activity in TKI-resistant Ph...
Clinical impact of panel-based next-generation sequencing in a real-world cohort of neuroblastoma patients.
10028 Background: Neuroblastoma is a malignant childhood tumor with a low somatic mutation rate, making targeted therapy c...
Smoking–genomic discordance in metastatic non–small cell lung cancer.
8543 Background: Smoking is the dominant risk factor for lung cancer, yet clinical smoking history does not consistently a...
Interception of molecular relapse in breast cancer: The SURVIVE HERoes study (NCT06643585).
TPS646 Background: Current research on circulating tumor DNA (ctDNA) in the adjuvant setting of early breast cancer (eBC)...
Baseline and on-treatment dynamics of <i>BRAF</i> V600E circulating tumor DNA in metastatic colorectal cancer: A systematic review and meta-analysis.
e15570 Background: BRAF V600E–mutated metastatic colorectal cancer (mCRC) represents a biologically di...
Spatial interactions between immune cells as a predictor of pCR to neoadjuvant chemotherapy (NACT) and nivolumab for ER+/HER2− breast cancer (BC): Analysis of the phase II GIADA trial.
567 Background: Adding an immune checkpoint inhibitor (ICI) to NACT increases pathological complete response (pCR) rates i...
Self-expandable metallic versus plastic biliary stents in malignant biliary obstruction: A systematic review and meta-analysis.
e16248 Background: Malignant biliary obstruction requires effective palliation with endoscopic stent placement and being t...
Low-dose apatinib combination with first-line chemotherapy rechallenge in advanced osteosarcoma: A single-center ambispective cohort study.
11529 Background: First-line treatment for osteosarcoma includes various combinations of four agents: high-dose methotrexa...
Preclinical activity of homoharringtonine against melanoma leptomeningeal disease using patient-derived tumor cells.
2024 Background: Leptomeningeal disease arising from melanoma (M-LMD) is a rare and highly aggressive form of metastasis a...
Exosomal microRNAs and key pathways associated with cognitive impairment in breast cancer patients: A longitudinal study.
e24098 Background: As mediators of intercellular communication, exosomal microRNAs (miRNAs) serve as promising biomarkers...
Predicting progression-free and overall survival from response endpoints in oncology clinical trials: An embedding-based machine learning approach.
e13666 Background: Objective response rate (ORR) and duration of response (DoR) provide important early efficacy signals i...
Comparative effectiveness and toxicity of CAR-T therapy versus blinatumomab in adult B-cell acute lymphoblastic leukemia: A real-world propensity-matched analysis.
6551 Background: Chimeric antigen receptor T-cell (CAR-T) therapy and blinatumomab are established treatment options for r...